Study Treatment Groups
| Treatment Group . | Dose of SCF (μg/kg/d) . | Dose of Filgrastim (μg/kg/day) . | Duration of Dosing (μg/kg/d) . | Leukapheresis . | No. of Leukapheresis Products Infused* . | No. of Patients . |
|---|---|---|---|---|---|---|
| . | . | . | . | (day of collection phase) . | . | . |
| A | 0 | 10 | 7 | 5-7 | 3 | 35 |
| B | 0 | 10 | 7 | 5-7 | 1 | 7 |
| C | 10 | 10 | 7 | 5-7 | 3 | 25 |
| D | 15 | 10 | 7 | 5-7 | 3 | 15 |
| E | 20 | 10 | 7 | 5-7 | 3 | 27 |
| F | 20 | 10 | 7 | 5-7 | 1 | 8 |
| G | 25 | 10 | 7 | 5-7 | 1 | 9 |
| H | 30 | 10 | 7 | 5-7 | 1 | 3 |
| I | 20 | 10 | 10 | 8-10 | 3 | 15 |
| J | 5 | 10 | 13 | 11-13 | 3 | 6 |
| K | 10 | 10 | 13 | 11-13 | 3 | 11 |
| L | 15 | 10 | 13 | 11-13 | 3 | 12 |
| M | 20 | 10 | 13 | 11-13 | 3 | 11 |
| N | 5 | 0 | 13 | 11-13 | 3 | 5 |
| 189 (Total) |
| Treatment Group . | Dose of SCF (μg/kg/d) . | Dose of Filgrastim (μg/kg/day) . | Duration of Dosing (μg/kg/d) . | Leukapheresis . | No. of Leukapheresis Products Infused* . | No. of Patients . |
|---|---|---|---|---|---|---|
| . | . | . | . | (day of collection phase) . | . | . |
| A | 0 | 10 | 7 | 5-7 | 3 | 35 |
| B | 0 | 10 | 7 | 5-7 | 1 | 7 |
| C | 10 | 10 | 7 | 5-7 | 3 | 25 |
| D | 15 | 10 | 7 | 5-7 | 3 | 15 |
| E | 20 | 10 | 7 | 5-7 | 3 | 27 |
| F | 20 | 10 | 7 | 5-7 | 1 | 8 |
| G | 25 | 10 | 7 | 5-7 | 1 | 9 |
| H | 30 | 10 | 7 | 5-7 | 1 | 3 |
| I | 20 | 10 | 10 | 8-10 | 3 | 15 |
| J | 5 | 10 | 13 | 11-13 | 3 | 6 |
| K | 10 | 10 | 13 | 11-13 | 3 | 11 |
| L | 15 | 10 | 13 | 11-13 | 3 | 12 |
| M | 20 | 10 | 13 | 11-13 | 3 | 11 |
| N | 5 | 0 | 13 | 11-13 | 3 | 5 |
| 189 (Total) |
An additional 26 patients who were mobilized to a target CD34+ cell yield received cytokine for 5 to 9 days; 13 received 15 μg/kg/d SCF and 10 μg/kg/d filgrastim and 13 received 10 μg/kg/d filgrastim alone. In total, 189 patients were evalueated for efficacy and 215 for safety.
Patients receiving only 1 leukapheresis product back were infused the first product collected.